SCHEMBL2883258

SCHEMBL2883258

O=C(c1ccc(F)c(F)c1)c1ncc(Br)cn1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES2 O00748 2/20 0.48
CES1 P23141 2/20 0.48
VNN1 O95497 5/20 0.44
KCNQ3 O43525 6/20 0.43
KCNQ2 O43526 6/20 0.43
KCNQ5 Q9NR82 1/20 0.43
KCNE1 P15382 1/20 0.41
KCNQ1 P51787 1/20 0.41
CYP11B1 P15538 1/20 0.39
CYP11B2 P19099 1/20 0.39
IGFBP3 P17936 1/20 0.39
NPC1 O15118 1/20 0.38
MAPT P10636 1/20 0.38
NFKB1 P19838 1/20 0.38
RAB9A P51151 1/20 0.38
NFKB2 Q00653 1/20 0.38
KMT2A Q03164 1/20 0.38
RELA Q04206 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
CHRNA7 P36544 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4066477 0.81 CES2 (0.46) CES2CES1VNN1KCNQ3KCNQ2
SCHEMBL238839 0.80 OPRK1 (0.39) VNN1MAPTKMT2ASMN1; SMN2CHRNA7
SCHEMBL4068874 0.80 CES2 (0.44) CES2CES1VNN1KCNQ3KCNQ2
SCHEMBL2882494 0.76 CES2 (0.43) CES2CES1VNN1KCNQ3KCNQ2
SCHEMBL7967901 0.75 CES2 (0.73) CES2CES1VNN1KCNQ3KCNQ2
SCHEMBL2314020 0.73 ALOX15 (0.53) VNN1NPC1MAPTRAB9AKMT2A
SCHEMBL12975496 0.71 VNN1 (0.56) CES2CES1VNN1KCNQ3KCNQ2
SCHEMBL12975504 0.71 VNN1 (0.54) CES2CES1VNN1KCNQ3KCNQ2
SCHEMBL22074902 0.71 CES1 (0.54) CES2CES1VNN1KCNQ3KCNQ2
SCHEMBL2882824 0.68 VNN1 (0.42) CES2CES1VNN1KCNQ3KCNQ2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100324049-A1 DIARYL KETIMINE DERIVATIVE HAVING ANTAGONISM AGAINST MELANIN-CONCENTRATING HORMONE RECEPTOR MSD K.K. (JP) 2010-12-23 US disclosed
US-20090247560-A1 Diaryl ketimine derivative BANYU PHARMACEUTICAL CO., LTD. 2009-10-01 US disclosed
EP-2072519-A1 DIARYL KETIMINE DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 2009-06-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100324049-A1 DIARYL KETIMINE DERIVATIVE HAVING ANTAGONISM AGAINST MELANIN-CONCENTRATING HORMONE RECEPTOR MC1R, MCHR1, MCHR2 CES2 2828/4885CES1 1529/4885VNN1 4191/4885
US-20090247560-A1 Diaryl ketimine derivative NR0B2, NR2C2, NR3C2 CES2 1262/4885CES1 758/4885VNN1 4382/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.